Analyst Ratings For NASDAQ:FIXX – Homology Medicines (NASDAQ:FIXX)
Today, BTIG Research initiated coverage on NASDAQ:FIXX – Homology Medicines (NASDAQ:FIXX) with a Buy with a price target of $35.00.
Some recent analyst ratings include
- 4/24/2018-BTIG Research initiated coverage with a Buy rating.
- 4/23/2018-Bank of America initiated coverage with a Buy rating.
- 4/23/2018-Evercore ISI initiated coverage with a Outperform rating.
- 4/23/2018-Cowen initiated coverage with a Outperform rating.
- On 4/2/2018 James E Flynn, Insider, bought 1,250,000 with an average share price of $16.00 per share and the total transaction amounting to $20,000,000.00.
- On 4/2/2018 Vida Ventures, Llc, Major Shareholder, bought 375,000 with an average share price of $16.00 per share and the total transaction amounting to $6,000,000.00.
Recent Trading Activity for NASDAQ:FIXX – Homology Medicines (NASDAQ:FIXX)
Shares of NASDAQ:FIXX – Homology Medicines closed the previous trading session at 20.50 up +0.60 3.02% with shares trading hands.